Literature DB >> 11855583

Hansenula anomala outbreak at a surgical intensive care unit: a search for risk factors.

S Kalenic1, M Jandrlic, V Vegar, N Zuech, A Sekulic, E Mlinaric-Missoni.   

Abstract

During a 5-month period, Hansenula anomala (H. anomala), an opportunistic fungus, caused an outbreak of infections in eight adult patients treated at a surgical intensive care unit (ICU). The source of the infections and route of transmission could not be identified. A case-control study included 32 patients treated simultaneously at the surgical ICU. Univariate analysis pointed to the following significant risk factors: blood alkalosis, reduced urea, duration of hospitalization, bacteremia and colonization with Pseudomonas aeruginosa, and an APACHE II score >17 (during bacteremia or fungemia). The stepwise logistic regression multivariate analysis showed only the duration of blood alkalosis to be significant in case patients.

Entities:  

Mesh:

Year:  2001        PMID: 11855583     DOI: 10.1023/a:1013739802940

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  23 in total

1.  Hansenula anomala infections in children: from asymptomatic colonization to tissue invasion.

Authors:  A Moses; S Maayan; Y Shvil; A Dudin; I Ariel; A Thalji; I Polacheck
Journal:  Pediatr Infect Dis J       Date:  1991-05       Impact factor: 2.129

2.  Catheter-related fungemia by Hansenula anomala.

Authors:  P Muñoz; M E Garcia Leoni; J Berenguer; J C Bernaldo de Quiros; E Bouza
Journal:  Arch Intern Med       Date:  1989-03

3.  Development of Hansenula anomala infection in a child receiving fluconazole therapy.

Authors:  S J Alter; J Farley
Journal:  Pediatr Infect Dis J       Date:  1994-02       Impact factor: 2.129

4.  Fungaemia caused by Hansenula anomala--an outbreak in a cancer hospital.

Authors:  L C Thuler; S Faivichenco; E Velasco; C A Martins; C R Nascimento; I A Castilho
Journal:  Mycoses       Date:  1997-10       Impact factor: 4.377

Review 5.  New and emerging yeast pathogens.

Authors:  K C Hazen
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

6.  Infective endocarditis of a bicuspid aortic valve caused by Hansenula anomala.

Authors:  B Nohinek; C S Zee-Cheng; W G Barnes; L Dall; H R Gibbs
Journal:  Am J Med       Date:  1987-01       Impact factor: 4.965

7.  Trends and sources of nosocomial fungaemia.

Authors:  G D Taylor; M Buchanan-Chell; T Kirkland; M McKenzie; R Wiens
Journal:  Mycoses       Date:  1994 Jun-Jul       Impact factor: 4.377

8.  Fungemia caused by Hansenula anomala: successful treatment with fluconazole.

Authors:  S Hirasaki; T Ijichi; N Fujita; S Araki; H Gotoh; M Nakagawa
Journal:  Intern Med       Date:  1992-05       Impact factor: 1.271

9.  An autopsy study of systemic fungal infections in patients with hematologic malignancies.

Authors:  M Jandrlić; S Kalenić; B Labar; D Nemet; J Jakić-Razumović; M Mrsić; V Plecko; V Bogdanić
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-09       Impact factor: 3.267

10.  Metabolic alkalosis in children undergoing cardiac surgery.

Authors:  H R Wong; K R Chundu
Journal:  Crit Care Med       Date:  1993-06       Impact factor: 7.598

View more
  3 in total

1.  In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods.

Authors:  D J Diekema; S A Messer; L B Boyken; R J Hollis; J Kroeger; S Tendolkar; M A Pfaller
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

2.  Risk factors and biofilm formation analyses of hospital-acquired infection of Candida pelliculosa in a neonatal intensive care unit.

Authors:  Zhijie Zhang; Yu Cao; Yanjian Li; Xufang Chen; Chen Ding; Yong Liu
Journal:  BMC Infect Dis       Date:  2021-06-29       Impact factor: 3.090

3.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.